Skip to content
Partners4Access
Expert global consultancy specializing in access for orphan drugs
Partners4Access
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact
Search:
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact

Daily Archives: May 22, 2020

You are here:
  1. Home
  2. 2020
  3. May
  4. 22

Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?

BlogsBy partnersadminMay 22, 2020

By Max Rex, Associate Consultant Email: mrex@partners4access.com Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green light by the European Medicines Agency on 19th May. The therapy has previously been approved in the US and Japan, and has already generated sales of over $500 million dollars…

TwitterInstagramLinkedin

All Rights Reserved © Privacy Partners 4 Access 2020

Go to Top